Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

ImmuPharma PLC

Healthcare GB IMM

4.5625GBX
-0.2225(4.65%)

Last update at 2026-06-11T15:14:00Z

Day Range

4.334.89
LowHigh

52 Week Range

1.3919.40
LowHigh

Fundamentals

  • Previous Close 4.79
  • Market Cap31.45M
  • Volume1453513
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-3.13515M
  • Revenue TTM-0.06996M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.06996M
  • Diluted EPS TTM-0.01

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -2.77900M -3.41900M -4.45633M -8.94072M -7.24618M
Minority interest - - - - -
Net income -2.48300M -2.92200M -3.80743M -8.17390M -6.85993M
Selling general administrative 1.03M 1.02M 0.85M 1.01M 1.76M
Selling and marketing expenses 0.09M 0.14M - - -
Gross profit -0.06388M -0.03761M - 0.12M 0.13M
Reconciled depreciation 0.06M 0.04M 0.12M 0.11M 0.17M
Ebit -2.67488M -3.06261M -3.02895M -6.58695M -5.58943M
Ebitda -2.61100M -3.02500M -2.88280M -5.04465M -5.37739M
Depreciation and amortization 0.06M 0.04M 0.15M 1.54M 0.21M
Non operating income net other - - - - -
Operating income -2.28000M -3.06300M -3.02895M -6.58695M -5.58943M
Other operating expenses 2.67M 3.06M 3.03M 5.28M 5.72M
Interest expense 0.00198M 0.00199M 1.46M 2.35M 1.70M
Tax provision -0.29587M -0.49710M -0.64890M -0.76681M -0.38625M
Interest income 0.00624M 0.00302M 0.03M 0.00065M 0.04M
Net interest income 0.00425M 0.00104M -1.42738M -0.20525M -1.65674M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.29587M -0.49700M -0.64890M -0.76682M -0.38625M
Total revenue 0.00000M 0.00000M 0.00000M 0.12M 0.13M
Total operating expenses 2.67M 3.15M 3.03M 5.28M 5.72M
Cost of revenue 0.06M 0.04M - - -
Total other income expense net -0.10400M -0.35600M -1.42738M -2.35377M -1.65674M
Discontinued operations - - - - -
Net income from continuing ops -2.48350M -2.92179M -3.80743M -8.17391M -6.85993M
Net income applicable to common shares - - - -8.17390M -6.85993M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 0.98M 2.72M 3.97M 6.00M 10.92M
Intangible assets 0.00982M 0.45M 0.47M 0.48M 0.48M
Earning assets - - - - -
Other current assets 0.22M 0.68M - 1.75M 1.57M
Total liab 1.52M 1.67M 1.45M 1.58M 1.26M
Total stockholder equity -0.54286M 1.06M 2.52M 4.41M 9.65M
Deferred long term liab - - 0.40M 0.40M 0.40M
Other current liab 0.89M 0.77M 0.18M 0.43M 0.20M
Common stock 29.81M 29.81M 28.98M 28.50M 25.02M
Capital stock 29.81M 29.81M 28.98M 28.50M 25.02M
Retained earnings -65.91114M -64.08291M -61.11532M -56.58163M -45.96635M
Other liab - - - - -
Good will - - - - -
Other assets - 0.00000M 0.49M 0.41M 0.58M
Cash 0.24M 0.21M 0.67M 1.65M 5.86M
Cash and equivalents - - - - -
Total current liabilities 1.52M 1.67M 1.45M 1.58M 1.26M
Current deferred revenue - - - - -
Net debt -0.23690M -0.20848M -0.66770M -1.64867M -5.22022M
Short term debt - - 0.00011M 0.00070M 0.64M
Short long term debt - 0.00000M 0.00011M 0.00070M 0.64M
Short long term debt total - - 0.00011M 0.00070M 0.64M
Other stockholder equity 35.56M 29.32M 34.66M 32.50M 30.60M
Property plant equipment - - - 0.35M 0.41M
Total current assets 0.88M 1.34M 2.34M 3.35M 7.43M
Long term investments - - - - -
Net tangible assets - - 2.45M 3.94M 9.57M
Short term investments - - - - -
Net receivables 0.43M 0.45M 0.72M 1.19M 0.48M
Long term debt - - - - -
Inventory - 0.00000M - - -
Accounts payable 0.51M 0.78M 1.45M 1.58M 0.62M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 6.01M - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 25.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.18M 0.77M 1.82M 2.59M
Deferred long term asset charges - - - - -
Non current assets total 0.09M 1.38M 1.64M 2.65M 3.49M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 1.29M 0.19M -0.07742M -0.05028M -0.25000M
Change to liabilities - - - 0.90M 0.11M
Total cashflows from investing activities 1.29M 0.19M - -0.05028M -0.56920M
Net borrowings - - - -0.72298M 1.32M
Total cash from financing activities 0.50M 0.72M 1.55M 0.70M 8.37M
Change to operating activities - - - - -
Net income -2.48350M -2.92179M -3.02895M -6.58695M -5.58943M
Change in cash 0.03M -0.45933M -0.98156M -4.21268M 4.50M
Begin period cash flow 0.21M 0.67M 1.65M 5.86M 1.36M
End period cash flow 0.24M 0.21M 0.67M 1.65M 5.86M
Total cash from operating activities -1.76910M -1.36441M -2.34707M -4.83317M -3.32940M
Issuance of capital stock 0.00000M 1.48M 2.35M 3.55M 8.00M
Depreciation 0.06M 0.04M 0.12M 0.11M 0.17M
Other cashflows from investing activities 0.00624M 0.19M - 0.00065M 0.04M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.21M 0.26M - -0.26520M -0.00838M
Sale purchase of stock - - - - 8.00M
Other cashflows from financing activities 0.50M -0.75859M -0.80318M -2.12498M 1.21M
Change to netincome - - - 2.60M 3.25M
Capital expenditures 0.00165M 0.00000M 0.11M 0.05M 0.36M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.07M 0.47M -0.42878M 0.63M 0.11M
Stock based compensation 0.09M 0.14M 0.16M 0.62M 1.58M
Other non cash items 0.49M 0.91M 0.83M 0.39M 0.41M
Free cash flow -1.77076M -1.36441M -2.45307M -4.88411M -3.68969M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
IMM
ImmuPharma PLC		 -0.2225 4.65% 4.56 - - 60.75 85.24 73.62 -0.9408
GNS
Genus PLC		 28.00 1.29% 2198.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 2.00 1.67% 122.00 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 7.00 1.15% 617.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 - -% 68.50 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company's lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired autoimmune disorder of peripheral nerve; and P140 that covers other indications acute and chronic asthma, gout, irritable bowel disease, and periodontitis. Its pre-clinical products include BioAMB, a peptide-based drug of Amphotericin-B formulations for the treatment of serious and life-threatening fungal infections, such as aspergillosis; and BioCin, a vancomycin based treatment for anti-infection. It has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of 1P40 platform; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.

ImmuPharma PLC

One Bartholomew Close, London, United Kingdom, EC1A 7BL

Key Executives

Name Title Year Born
Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A., MBA Chairman & CEO 1957
Dr. Timothy Gary Franklin M.B.A., Ph.D. COO & Director NA
Ms. Lisa Baderoon Head of Investor Relations & Non Exec. Director NA
Dr. Jean-Marie Geiger PharmD, MD Head of Clinical Devel. NA
Dr. Laura Mauran-Ambrosino Chief Scientific Officer of ImmuPharma Biotech NA
Dr. Sébastien R. Goudreau Ph.D. Chief Exec. Officer of ImmuPharma Biotec NA
Mr. Timothy Paul McCarthy XIV, FCCA, M.B.A. Chairman & CEO 1956
Dr. Timothy Gary Franklin M.B.A., Ph.D. COO & Director 1964
Dr. Sebastien R. Goudreau Ph.D. Chief Scientific Officer & Director 1981
Ms. Lisa Baderoon Head of Investor Relations & Non Executive Director 1966

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions